Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Tuberculosis (TB) continues to be an important comorbidity in patients with chronic kidney disease (CKD) on long-term dialysis, especially in countries like India that contribute nearly one-quarter of the global TB burden (India TB Report 2024). Tamil Nadu reports an incidence of around 170 per 100,000 population, with a parallel rise in CKD prevalence and dialysis dependence. CKD 5D patients are particularly vulnerable because of impaired immunity, malnutrition, diabetes, and repeated hospital exposure. Despite this, clinical data describing the pattern and outcome of TB in the Indian dialysis population are limited. This study was undertaken to describe the spectrum of disease, treatment response, and drug-related adverse effects in CKD 5D patients managed at a tertiary centre in southern India
We carried out a retrospective observational study of CKD 5D patients on maintenance haemodialysis who were diagnosed with tuberculosis between January 2022 and August 2025.Ethical approval obtained from institutional review board.Inclusion criteria were adults (≥18 years) on dialysis for ≥6 months with confirmed or probable TB based on clinical, radiological, or microbiological evidence.Exclusion criteria included peritoneal dialysis, incomplete documentation, or alternative diagnoses.Patient demographics, comorbidities, dialysis vintage, site of infection, anti-tubercular therapy (ATT) regimen, adverse reactions, and outcomes were reviewed. ATT was prescribed with renal dose modifications and close monitoring for hepatotoxicity or neurotoxicity. Clinical and radiological improvement, as well as survival, were assessed at 6 and 12 months.
Twelve patients (8 men, 4 women; mean age 52 ± 13 years) were included. Mean dialysis vintage was 4.2 years. Diabetes and hypertension were present in 66 % and 83 % respectively. Extrapulmonary disease was predominant (83 %), with pleural effusion (41.6 %) as the most frequent presentation, followed by skeletal (16.6 %), peritoneal (16.6 %)-Figure 1, lymph-node (8.3 %), pericardial (8.3 %), and disseminated (8.3 %) TB. All patients received renal-adjusted ATT, most commonly rifampicin, isoniazid, levofloxacin, and pyrazinamide on alternate days. Adverse effects occurred in three patients (25 %)—hepatotoxicity in one, neuropsychiatric symptoms in one, and gastrointestinal intolerance in one. Two required regimen modification, and two (16.6 %) died of sepsis during therapy. Overall, 75 % showed clinical and radiological improvement, with 60 % completing the full course of ATT. The average time to symptomatic improvement was 6–8 weeks.
In our experience Extrapulmonary involvement dominates , and infection-related mortality remains considerable despite appropriate, renal-adjusted therapy. The coexistence of diabetes, long dialysis vintage, and recurrent hospital exposure further increases risk. Early suspicion, routine screening for latent TB, and individualized dosing are essential to improve outcomes. Larger multicentric studies and a dedicated dialysis-TB registry could help develop uniform diagnostic and treatment protocols for this vulnerable population.highlights the hidden burden and atypical presentation of tuberculosis among CKD 5D patients in Tamil Nadu.
